Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $28.8 million.

  • Legend Biotech's Cash from Operations rose 13798.5% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$204.1 million, marking a year-over-year decrease of 2949.87%. This contributed to the annual value of -$178.0 million for FY2024, which is 5948.48% up from last year.
  • As of Q3 2025, Legend Biotech's Cash from Operations stood at $28.8 million, which was up 13798.5% from -$13.0 million recorded in Q2 2025.
  • Legend Biotech's Cash from Operations' 5-year high stood at $28.8 million during Q3 2025, with a 5-year trough of -$198.5 million in Q4 2021.
  • Its 5-year average for Cash from Operations is -$62.5 million, with a median of -$60.8 million in 2023.
  • In the last 5 years, Legend Biotech's Cash from Operations tumbled by 1308486.49% in 2023 and then surged by 13798.5% in 2025.
  • Over the past 5 years, Legend Biotech's Cash from Operations (Quarter) stood at -$198.5 million in 2021, then skyrocketed by 74.94% to -$49.7 million in 2022, then plummeted by 92.28% to -$95.6 million in 2023, then decreased by 21.38% to -$116.1 million in 2024, then skyrocketed by 124.81% to $28.8 million in 2025.
  • Its last three reported values are $28.8 million in Q3 2025, -$13.0 million for Q2 2025, and -$103.8 million during Q1 2025.